dc.contributor.author |
Climent, Miguel Ángel |
dc.contributor.author |
Álvarez, Carlos |
dc.contributor.author |
Morales-Barrera, Rafael |
dc.contributor.author |
Maroto, Pablo |
dc.contributor.author |
Rodríguez-Vida, Alejo |
dc.contributor.author |
Méndez-Vidal, María José |
dc.contributor.author |
García del Muro, Xavier |
dc.contributor.author |
Puente, Javier |
dc.contributor.author |
Láinez, Nuria |
dc.contributor.author |
Vázquez, Sergio |
dc.contributor.author |
Castellano, Daniel |
dc.contributor.author |
Gómez Lang, Carmen |
dc.contributor.author |
Wang, Jing |
dc.contributor.author |
Di Pietro, Alessandra |
dc.contributor.author |
Davis, Craig |
dc.contributor.author |
Sanz Castillo, Belén |
dc.contributor.author |
Bolós, M. Victoria |
dc.contributor.author |
Valderrama, Begoña P. |
dc.date.accessioned |
2024-10-09T06:25:09Z |
dc.date.available |
2024-10-09T06:25:09Z |
dc.date.issued |
2024 |
dc.identifier.citation |
Climent MÁ, Álvarez C, Morales R, Maroto P, Rodríguez-Vida A, Méndez-Vidal MJ, et al. Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial. Clin Transl Oncol. 2024 Jun;26(6):1532-8. DOI: 10.1007/s12094-023-03358-4 |
dc.identifier.issn |
1699-048X |
dc.identifier.uri |
http://hdl.handle.net/10230/61360 |
dc.description.abstract |
Purpose: Post hoc analysis of the JAVELIN Bladder 100 trial of avelumab maintenance in locally advanced/metastatic urothelial carcinoma (la/mUC) to determine the interaction by programmed death ligand 1 (PD-L1) status for overall survival (OS), and additional analyses of survival per a different PD-L1 expression cutoff of ≥ 1% in tumor cells or immune cells (TC/IC). Methods: JAVELIN Bladder 100 data were used for the analysis of the interaction by PD-L1 status (per cutoff used in the trial) for OS and, additionally, OS and progression-free survival (PFS) analyses per a different ≥ 1% TC/IC PD-L1 expression cutoff (Ventana SP263 assay). Results: No significant interaction between treatment and PD-L1 status was observed for OS. Clinically meaningful and robust survival data were observed in favor of avelumab using the different ≥ 1% TC/IC PD-L1 expression cutoff. Conclusions: These results demonstrate the benefit of avelumab maintenance in la/mUC regardless of PD-L1 expression, consistent with approved labels. |
dc.format.mimetype |
application/pdf |
dc.language.iso |
eng |
dc.publisher |
Springer |
dc.relation.ispartof |
Clin Transl Oncol. 2024 Jun;26(6):1532-8 |
dc.rights |
© The Author(s) 2023, corrected publication 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
dc.rights.uri |
http://creativecommons.org/licenses/by/4.0/ |
dc.title |
Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial |
dc.type |
info:eu-repo/semantics/article |
dc.identifier.doi |
http://dx.doi.org/10.1007/s12094-023-03358-4 |
dc.subject.keyword |
Advanced urothelial carcinoma |
dc.subject.keyword |
Avelumab |
dc.subject.keyword |
Interaction test |
dc.subject.keyword |
Maintenance treatment |
dc.subject.keyword |
PD-L1 |
dc.rights.accessRights |
info:eu-repo/semantics/openAccess |
dc.type.version |
info:eu-repo/semantics/publishedVersion |